Guerbet Liver Fibrosis

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT06703450
Status
Enrolling By Invitation

Conditions

  • Metabolic Dysfunction-associated Steatotic Liver Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Accepted

Study Details

The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and blood tests in 50 initial patients with metabolic dysfunction-associated steatohepatitis (MASH).

Key Dates

Start date
Feb 28, 2024
Status verified
Apr 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Participants with liver disease
    Participants with liver disease for diagnosis of liver fibrosis to have DCE-MRI

Primary Outcome Measure

Liver Stiffness by MR Elastography [ Time Frame: during procedure (MRI) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mount SinaiNew YorkNew York10029-

Find similar trials in New York, NY

By research site
Mount Sinai· New York, NY

Related Studies